Bevacizumab in glioblastoma multiforme. - Wikidata - awgldk - TriplyDB

Bevacizumab in glioblastoma multiforme.

Bevacizumab in glioblastoma multiforme.

http://www.wikidata.org/entity/Q37965628

about

Migration capacity of human umbilical cord mesenchymal stem cells towards glioma in vivo Differences in molecular genetics between pediatric and adult malignant astrocytomas: age matters.Glioblastoma multiforme - an overview.miR-331-3p regulates expression of neuropilin-2 in glioblastoma.Parametric response maps of perfusion MRI may identify recurrent glioblastomas responsive to bevacizumab and irinotecan.Glioblastoma treatment patterns, survival, and healthcare resource use in real-world clinical practice in the USA.Efficacy and safety of bevacizumab for the treatment of glioblastoma.Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges.Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach.Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment.Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs).PinX1 inhibits cell proliferation, migration and invasion in glioma cells.A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas.

P2860

Q34095283-37A8D683-C9D5-4CEA-B0CC-B500A6F1B368 Q34286305-A03D2506-4D06-433B-8C86-A44850616EE9 Q34589068-01F762E0-D8B4-4A46-8FCF-5A389559EA70 Q35021427-47C26E33-C8C8-470C-B057-BF153E9D7182 Q35133246-18AE6D78-8CD1-4EBA-99C8-67190DA53327 Q35222941-932A33CF-21F8-4D5B-AB61-6F4E6EADAD37 Q36523864-B9DD105C-51B1-41BC-B557-63561E1C478B Q36787777-E1811C54-45D8-479E-BA8F-9623E16EA7CC Q38108186-2DF26A51-7252-451F-8665-45A01D2BCA87 Q38203283-7EE84F15-E828-46D0-BB45-DB4D11846074 Q38827793-C548ACA6-6788-47BE-A14A-9DEAC5FE4DF4 Q38907902-871196CC-4F84-4E87-B09A-6428DA5A65FE Q45094655-B7444184-1DB1-4539-817B-169AC439D933

P2860

Bevacizumab in glioblastoma multiforme.

http://www.wikidata.org/entity/Q37965628

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Bevacizumab in glioblastoma multiforme.

@en

Bevacizumab in glioblastoma multiforme.

@nl

type

label

Bevacizumab in glioblastoma multiforme.

@en

Bevacizumab in glioblastoma multiforme.

@nl

prefLabel

Bevacizumab in glioblastoma multiforme.

@en

Bevacizumab in glioblastoma multiforme.

@nl

P1433

Q37965628-A9F92F4B-8785-4CD2-8AD9-8509A03A0AFB

P1476

Q37965628-4C00CE22-31DB-4B53-A40F-53A74F13681F

P2093

Q37965628-7DCE2D41-39D8-422B-ABF4-20A4E4ED38A3

P2860

Q37965628-00F361AF-D5AB-422D-8387-57708F829794

Q37965628-0909F669-1CBE-47B2-99F0-F7A1EF4ADD5E

Q37965628-11718FB0-C54E-4688-876A-7F2A26561719

Q37965628-148B2B49-EC32-4FF7-999D-C200812C7C06

Q37965628-1619C1E3-15DD-4E2A-AA55-A8DC95E63886

Q37965628-193477E7-E368-43DA-A31F-6BEEF3E34988

Q37965628-1A47143A-99D0-466D-980B-B22ED272F53C

Q37965628-1F6BE437-4523-4813-9D01-C56BA6521DB4

Q37965628-2350C12B-8DC2-4A48-81BE-505E7D7B2F3C

Q37965628-293EEA7F-B721-44E5-A686-85821A69C440

P304

Q37965628-9C13588C-6A35-4D58-9030-8B646E8DF413

P31

Q37965628-32680354-861F-4921-A00C-98C550D2FF4E

P356

Q37965628-1D80918A-74B4-4083-B40A-F0EEB3FB425D

P433

Q37965628-0F28F71D-9A1B-43AA-AACE-BC39CAB6CB98

P478

Q37965628-CCB8B869-1073-4FAE-A2D3-08C82EAEA80E

P50

Q37965628-967ACFEE-5F9E-450F-AE2F-206D0EC5497F

P577

Q37965628-67B3364D-F996-44DA-9E38-DA35B52FF047

P698

Q37965628-C317F738-4E6F-4BD5-BFA2-2925284A52C5

P921

Q37965628-BFC40F8B-37CF-4D3C-B4F0-EA4DAE8C15AC

P356

P1433

Expert Review of Anticancer Therapy

P1476

Bevacizumab in glioblastoma multiforme

@en

P2093

Pol Specenier

http://www.w3.org/2001/XMLSchema#string

P2860

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Malignant gliomas in adults

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.

Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab.

Optic neuropathy in patients with glioblastoma receiving bevacizumab.

DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma.

Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

P304

9-18

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERA.11.179

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22149428

http://www.w3.org/2001/XMLSchema#string

P921